Abstract: A system (10) for remotely enabling and disabling a weapon (12), includes a watchdog controller (14) adapted to receive a safe/arm command from a remote source (16) and to transmit the safe/arm command if predetermined conditions are satisfied, a safe/arm controller (20) adapted to receive the safe/arm command from the watchdog controller (14) and to transmit a control signal to enable communication between a weapon system processor (24) and the weapon (12) if a predetermined series of input signals are received in a predetermined sequence. The system also includes a switch (22) in a communication path between the weapon system processor (24) and the weapon (12). The safe/arm controller (20) closes the switch (22) and enables communication between the weapon system processor (24) and the weapon (12) only when the safe/arm controller (20) receives an arm signal and receives the predetermined series of input signals in the predetermined sequence.

Abstract: A system (10) for remotely enabling and disabling a weapon (12), includes a watchdog controller (14) adapted to receive a safe/arm command from a remote source (16) and to transmit the safe/arm command if predetermined conditions are satisfied, a safe/arm controller (20) adapted to receive the safe/arm command from the watchdog controller (14) and to transmit a control signal to enable communication between a weapon system processor (24) and the weapon (12) if a predetermined series of input signals are received in a predetermined sequence. The system also includes a switch (22) in a communication path between the weapon system processor (24) and the weapon (12). The safe/arm controller (20) closes the switch (22) and enables communication between the weapon system processor (24) and the weapon (12) only when the safe/arm controller (20) receives an arm signal and receives the predetermined series of input signals in the predetermined sequence.

Abstract: The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSMA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSMA, the therapeutic drugs are activated and exert their toxicity. Sesquiterpene-?-lactones form part of the prodrugs, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.